Holding(s) in Company

Hutchison China Meditech Limited
22 April 2008





                  Hutchison China MediTech Limited ('Chi-Med')

                                   (AIM: HCM)


                               Holding in Company


London, Tuesday, 22 April 2008: Chi-Med today announces that it received
notification on 21 April 2008 from Cazenove Capital Management Limited
('Cazenove') that following the acquisition of 72,000 shares on 18 April 2008,
Cazenove is holding a total of 2,624,344 shares in Chi-Med, representing
approximately 5.12% of the total issued shares of Chi-Med.



                                      Ends



Enquiries


  Chi-Med                                    Telephone: [phone]
  Christian Hogg, CEO

  Citigate Dewe Rogerson                     Telephone: [phone]
  Anthony Carlisle                           [phone]
  David Dible                                [phone]

About Chi-Med


Chi-Med is the holding company of a pharmaceutical and healthcare group focused
on traditional Chinese medicine ('TCM') based primarily in China and was
admitted to trading on the Alternative Investment Market of the London Stock
Exchange in May 2006. Chi-Med operates three core business segments: 1) China
healthcare - the manufacture, distribution and marketing of pharmaceuticals and
health supplements in China; 2) Drug R&D - the discovery and global development
of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer
products - global retailing and distribution consumer health and personal care
products derived from TCM and botanical ingredients.



Chi-Med is majority owned by Hutchison Whampoa Limited, an international company
listed on the Main Board of The Stock Exchange of Hong Kong Limited.


                      This information is provided by RNS
            The company news service from the London Stock Exchange